Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29593884 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL29775131 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL1002064 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL163841 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL1161605 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL674106 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL3216510 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL5635861 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL163842 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D | |
| SCHEMBL29777394 | 1.00 | ANPEP (0.48) | ANPEPKDM1AHTR2ASIGMAR1GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1554 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4624455-A1 | PREPARATION METHOD FOR CHIRAL PYRROLE DERIVATIVE AND INTERMEDIATE THEREOF | Kangbaida (Sichuan) Biotechnology Co., Ltd. (CN) | 2025-10-01 | — | — | EP | claimed |
| US-20250276986-A1 | PREPARATION METHOD FOR CHIRAL PYRROLE DERIVATIVE AND INTERMEDIATE THEREOF | Kangbaida (Sichuan) Biotechnology Co., Ltd (CN) | 2025-09-04 | — | — | US | claimed |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | claimed |
| EP-3385252-B1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | claimed |
| US-20220234996-A1 | Method for Producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic Acid and the Crystalline Form Thereof for Use as a Pharmaceutical Ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | claimed |
| CN-114478630-A | Chiral diphosphine skeleton compound, preparation method and application thereof | 中国科学院上海有机化学研究所 | 2022-05-13 | — | — | CN | claimed |
| CN-109501318-B | Special-shaped section bar drawing and pressing process adopting PMI foam sandwich | 浙江中科恒泰新材料科技有限公司 | 2021-07-27 | — | — | CN | claimed |
| CN-113087640-A | Chiral ONO tridentate Schiff base carboxylic acid ligand and preparation method and application thereof | 合肥工业大学 | 2021-07-09 | — | — | CN | claimed |
| US-20210179541-A1 | Method for Producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic Acid and the Crystalline Form Thereof for Use as a Pharmaceutical Ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | US | claimed |
| US-20210060040-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | claimed |
| WO-1996036584-A1 | PROCESS FOR RESOLVING CHIRAL ACIDS WITH 1-AMINOINDAN-2-OLS | SEPRACOR, INC. (US) | 1996-11-21 | — | — | WO | claimed |
| EP-0719247-A1 | PROCESS FOR PREPARING CYCLIC CIS-1-AMINO-2-ALKANOLS | SEPRACOR, INC. (US) | 1996-07-03 | — | — | EP | claimed |
| US-5516943-A | Process for preparing cyclic CIS-1-amino-2-alkanols | SEPRACOR, INC. (US) | 1996-05-14 | — | — | US | claimed |
| US-5489710-A | AMINATION BY MIXING WITH NITRILE SOLVENT, ACIDIFICATION AND HYDROLYZING WITH WATER | MERCK & CO., INC. (US) | 1996-02-06 | — | — | US | claimed |
| WO-1995024375-A1 | REGIOSPECIFIC PROCESS TO MAKE CIS-1-AMINO-2-ALKANOL FROM EPOXIDE | MERCK & CO., INC. (US) | 1995-09-14 | — | — | WO | claimed |
| WO-1995024374-A1 | REGIOSPECIFIC PROCESSES TO MAKE CIS-1-AMINO-2-ALKANOL FROM DIOL OR HALOHYDRIN | MERCK & CO., INC. (US) | 1995-09-14 | — | — | WO | claimed |
| US-5449830-A | Enzyme inhibitors for protease encoded for HIV | MARCK & CO., INC. (US) | 1995-09-12 | — | — | US | claimed |
| EP-0658537-A1 | Method of producing cis-1-aminoindan-2-ol | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1995-06-21 | — | — | EP | claimed |
| US-5420353-A | Protease inhibitors, AIDS | MERCK & CO., INC. (US) | 1995-05-30 | — | — | US | claimed |
| WO-1995007880-A1 | PROCESS FOR PREPARING CYCLIC CIS-1-AMINO-2-ALKANOLS | SEPRACOR, INC. (US) | 1995-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220234996-A1 | Method for Producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic Acid and the Crystalline Form Thereof for Use as a Pharmaceutical Ingredient | FABP3, PCCA, HMGCR | ANPEP 499/4885KDM1A 3518/4885HTR2A 1543/4885 |
| US-20210060040-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | ANPEP 4453/4885KDM1A 2336/4885HTR2A 72/4885 |
| US-20250276986-A1 | PREPARATION METHOD FOR CHIRAL PYRROLE DERIVATIVE AND INTERMEDIATE THEREOF | PIN1, DHPS, PPOX | ANPEP 760/4885KDM1A 3769/4885HTR2A 3309/4885 |
| US-20210179541-A1 | Method for Producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic Acid and the Crystalline Form Thereof for Use as a Pharmaceutical Ingredient | FABP3, PCCA, HMGCR | ANPEP 499/4885KDM1A 3518/4885HTR2A 1543/4885 |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | ANPEP 2194/4885KDM1A 1799/4885HTR2A 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.